Mr Declan Doogan

KANDO id: 87949

Bio

Declan joined Fidelity Biosciences in October 2007, he has been in Pharmaceutical R&D for most of his professional life, starting first in the Netherlands as a project physician. He joined Pfizer in 1982, where he was in charge of the sertraline (Zoloft) clinical development program. He has held a number of senior positions in R&D in the US and the UK and Japan. He retired from Pfizer in April 2007 where he was Senior Vice President World Development. Dr. Doogan holds a number of Board appointments principally in pharmaceutical R&D but also Visiting Professor at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo). He is interested not only in the scientific aspects of drug development but also in defining new strategies to improve yield and effectiveness in human drug development. He is also involved in charities such as the Haitian Health Foundation, the Pulmonary Vascular Research Institute and Odessey, a cancer charity. Dr. Doogan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine in the UK.

Education